link to RWJMS home page

 

Banner Image Here

HafftyBruce G. Haffty, M.D., FASTRO

Professor
Chairman, Associate Director of the Cancer Institute of New Jersey
Tel: 732-235-5203
Emai: hafftybg@cinj.rutgers.edu

Click Here For Clinical Information

Education:

    • MD: Yale University
    • Residency: Yale University

Academic Appointments:

    • Professor

Honors/Certificates:One of America 's Top Doctors.

    • Fellow of ASTRO
    • One of The country's Top Physicians by Best Doctors in America ,
    • One of The Top Doctors by Ladies Home Journal
    • One of The Top Doctors by Good Housekeeping
    • President of the Association of Directors of Radiation Oncology Programs (2000-2003)
    • Vice-chairman of the ACGME residency review committee for radiation oncology.
    • Trustee of the American Board of Radiology
    • Chairman of the Breast Exam Committee of the ABR
    • Assistant Executive Director of the ABR
    • The scientific advisory board of the American Society of Breast Surgeons Mammosite Registry Trial
    • Member of the executive committee of the American College of Surgeons Commission on Cancer
    • Member of the executive committee of the American Radium Society
    • Member of several educational and scientific committees of ASTRO, American Radium Society, ASCO and RSNA.
    • Certificate of American Board of Radiology (Board Certified)

Research Interests:

Clinical and Translational Reserach: genetic markers in breast cancers and their roles in determination of the cancer managements.

Clinical Interests:

    • Breast Cancer
    • Head and Neck Cancer

Insurance Affiliations:

Selected Peer-Reviewed Publications for the Recent 5 Years:

    • Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG., Prognostic Value of Triple-Negative Phenotype at the Time of Locally Recurrent, Conservatively Treated Breast Cancer. Int J Radiat Oncol Biol Phys. 2008 Aug 1.
    • Yang Q, Moran MS, Haffty BG, Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat. 2008 May 31
    • White JR, Halberg FE, Rabinovitch R, Green S, Haffty BG, Solin LJ, Strom EA, Taylor ME, Edge, SB, American College of Radiology appropriateness criteria on conservative surgery and radiation: stages I and II breast carcinoma. J Am Coll Radiol. 2008 Jun;5(6):701-13.
    • Haffty BG, Buchholz TA, McCormick B, Should intensity-modulated radiation therapy be the standard of care in the conservatively managed breast cancer patient? J Clin Oncol. 2008 May 1;26(13):2072-4. Epub 2008 Feb 19.
    • Haffty BG, Yang Q, Moran MS, Tan AR, Reiss M, Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1006-13.
    • Choi DH, Cho DY, Lee MH, Park HS, Ahn SH, Son BH, Haffty BG., The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. Breast Cancer Res Treat. 2008 Jan 3
    • Yue NJ , Kim S, Jabbour S, Narra V, Haffty BG., A strategy to objectively evaluate the necessity of correcting detected target deviations in image guided radiotherapy. Med Phys. 2007 Nov;34(11):4340-7.
    • Chang S, Zhou J, Liu Q, Metaxas DN, Haffty BG, Kim SN, Jabbour SJ, Yue NJ., Registration of lung tissue between fluoroscope and CT images: determination of beam gating parameters in radiotherapy. Med Image Comput Comput Assist Interv Int Conf Med Image Comput Comput Assist Interv. 2007;10(Pt 1):751-8.
    • Smith BD, Haffty BG, Smith GL, Hurria A, Buchholz TA, Gross CP., Use of postmastectomy radiotherapy in older women. Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):98-106. Epub 2007 Nov 8.
    • Wilson LD, Yu JB, Haffty BG., National Residency Matching Program (NRMP) results for radiation oncology: 2007 update. Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):326-7.
    • Parikh RR, Yang Q, Higgins SA, Haffty BG., Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):35-42. Epub 2007 Sep 12.
    • Yue NJ , Haffty BG, Yue J., On the assay of brachytherapy sources. Med Phys. 2007 Jun;34(6):1975-82.
    • Edvardsen H, Tefre T, Jansen L, Vu P, Haffty BG, Fosså SD, Kristensen VN, Børresen-Dale AL., Linkage disequilibrium pattern of the ATM gene in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity and post-lumpectomy local recurrence. Radiat Oncol. 2007 Jul 10; 2:25 .
    • Ho AY, Fan G, Atencio DP, Green S, Formenti SC, Haffty BG, Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS., Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):677-84. Epub 2007 May 22.
    • Goyal S, Kearney T, Haffty BG., Current application and research directions for partial-breast irradiation. Oncology ( Williston Park ). 2007 Apr;21(4):449-61; discussion 461-2, 464, 470. Review.
    • Kun LE, Haffty BG, Bosma J, Strife JL, Hattery RR., American Board of Radiology Maintenance of Certification - Part IV: practice quality improvement for radiation oncology. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):7-12.
    • Buchholz TA, Haffty BG, Harris JR., Should all patients undergoing breast conserving therapy for DCIS receive radiation therapy? Yes. Radiation therapy, an important component of breast conserving treatment for patients with ductal carcinoma in situ of the breast. J Surg Oncol . 2007 Jun 15; 95 ( 8 ): 610-3
    • Parikh RR, Yang Q, Haffty BG., Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy. Cancer. 2007 Feb 1;109(3):566-73.
    • Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D., Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006 Dec 20;24(36):5652-7. Epub 2006 Nov 20.
    • Smith BD, Haffty BG, Hurria A, Galusha DH, Gross CP., Postmastectomy radiation and survival in older women with breast cancer. J Clin Oncol. 2006 Oct 20;24(30):4901-7.
    • Wilson LD, Haffty BG., National Residency Matching Program results for radiation oncology: 2006 update. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):321-2.
    • Floyd SR, Buchholz TA, Haffty BG, Goldberg S, Niemierko A, Raad RA, Oswald MJ, Sullivan T, Strom EA, Powell SN, Katz A, Taghian AG., Low local recurrence rate without postmastectomy radiation in node-negative breast cancer patients with tumors 5 cm and larger. Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):358-64. Epub 2006 Aug 2.
    • Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B , Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55.
    • Lally BE, Zelterman D, Colasanto JM, Haffty BG , Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol. 2006 Jul 1;24(19):2998-3006. Epub 2006 Jun 12.
    • Jeruss JS, Vicini FA, Beitsch PD, Haffty BG , Quiet CA, Zannis VJ, Keleher AJ, Garcia DM, Snider HC, Gittleman MA, Whitacre E, Whitworth PW, Fine RE, Arrambide S, Kuerer HM. Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast. Ann Surg Oncol. 2006 Jul;13(7):967-76. Epub 2006 May 16.
    • Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG , Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006 Jun 1;24(16):2437-43. Epub 2006 Apr 24.
    • Choi DH, Lee MH, Haffty BG . Double heterozygotes for non-Caucasian families with mutations in BRCA-1 and BRCA-2 genes. Breast J. 2006 May-Jun;12(3):216-20.
    • Kwong MS, Chung GG, Horvath LJ, Ward BA, Hsu AD, Carter D, Tavassoli F, Haffty B , Burtness BA. Postchemotherapy MRI overestimates residual disease compared with histopathology in responders to neoadjuvant therapy for locally advanced breast cancer. Cancer J. 2006 May-Jun;12(3):212-21.
    • Haffty BG , Kim JH, Yang Q, Higgins SA. Concurrent chemo-radiation in the conservative management of breast cancer. Int J Radiat Oncol Biol Phys. 2006 May 31; [Epub ahead of print].
    • Smith GL, Smith BD, Haffty BG . Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2006 May 31; [Epub ahead of print]
    • Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG . Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006 May 17;98(10):681-90.
    • Jeruss JS, Vicini FA, Beitsch PD, Haffty BG , Quiet CA, Zannis VJ, Keleher AJ, Garcia DM, Snider HC, Gittleman MA, Whitacre E, Whitworth PW, Fine RE, Arrambide S, Kuerer HM. Initial Outcomes for Patients Treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma-In-Situ of the Breast. Ann Surg Oncol. 2006 May 16; [Epub ahead of print].
    • Kim JH, Tavassoli F, Haffty BG . Chest wall relapse after mastectomy for ductal carcinoma in situ: a report of 10 cases with a review of the literature. Cancer J. 2006 Mar-Apr;12(2):92-101.
    • Haffty BG , Silber A, Matloff E, Chung J, Lannin D. Racial differences in the incidence of BRCA1 and BRCA2 mutations in cohort of early onset breast cancer patients: African American compared to White Women. J Med Genet. 2006 Feb;43(2):133-7. Epub 2005 Jun 27.
    • Weinberger PM, Yu Z, Haffty BG , Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus-Associated Oropharyngeal Cancers With Favorable Prognosis. J Clin Oncol. 2006 Feb 10;24(5):736-47.
    • Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG , Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA. Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology. 2005;69(5):372-83. Epub 2005 Nov 24.
    • Alpert TE, Kuerer HM, Arthur DW, Lannin DR, Haffty BG . Ipsilateral breast tumor recurrence after breast conservation therapy: Outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys. 2005 Nov 1;6(3):845-51.
    • Higgins SA, Matloff ET, Rimm DL, Dziura J, Haffty BG , King BL. Patterns of reduced nipple aspirate fluid production and ductal lavage cellularity in women at high risk for breast cancer. Breast Cancer Res. 2005;7(6):R1017-22. (Epub 2005 Oct 24).
    • Zannis V, Beitsch P, Vicini F, Quiet C, Keleher A, Garcia D, Snider H, Gittleman M, Kuerer H, Whitacre E, Whitworth P, Fine R, Haffty BG , Stolier A, Mabie J. Descriptions and outcomes of insertion techniques of a breast brachytherapy balloon catheter in 1403 patients enrolled in the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial. Am J Surg, 2005 Oct;190(4):530-8.
    • Choi DH, Kim S, Rimm DL, Carter D, Haffty BG . Immunohistochemical biomarkers in patients with early-onset breast carcinoma by tissue microarray. Cancer J. 2005 Sep-Oct;11(5):404-11.
    • Moran MS, Colasanto JM, Haffty BG , Wilson LD, Lund MW, Higgins SA. Effects of breast-conserving therapy on lactation after pregnancy. Cancer J. 2005 Sep-Oct;11(5):399-403.
    • Psyrri A, Yu Z, Weinberger PM, Sasaki C, Haffty BG , Camp R. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res. 2005 Aug 15;11(16):5856-62.
    • Vicini FA, Beitsch PD, Quiet CA, Keleher A, Garcia D, Snider HC, Gittleman MA, Zannis VJ, Kuerer H, Whitacre EB, Whitworth PW, Fine RE, Haffty BG , Arrambide LS. First analysis of patient demographics, technical reproducibility, cosmesis, and early toxicity: results of the American Society of Breast Surgeons MammoSite breast brachytherapy trial. Cancer, 2005 Sep 15;104(6):1138-48.
    • Solin LJ, Fourquet A, Vicini FA, Taylor M, Haffty BG , Strom EA, Wai E, Pierce LJ, Marks LB, Bartelink H, Campana F, McNeese MD, Jhingran A, Olivotto IA, Bijker N, Hwang WT. Salvage treatment for local or local-regional recurrence after initial breast conversation treatment with radiation for ductal carcinoma in situ. Eur J Cancer, 2005 Aug;41(12):1715-23.
    • Kim JH, Bossuyt V, Ponn T, Lannin D, Haffty BG . Cyclooxygenase-2 expression in post-mastectomy chest wall relapse. Clin Cancer Res. 2005 Jul 15;11(14):5199-205.
    • Yu-Nishino H, Tavassoli FA, Ahrens WA , Haffty BG . Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast conserving therapy (BCT). Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1040-7.
    • Wilson LD, Flynn DF, Haffty BG . Radiation oncology career decision variables for graduating trainees seeking positions in 2003-2004. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):519-25
    • Lally BE, Haffty BG , Moran MS, Colasanto JM, Higgins SA. Management of suspicious or indeterminate calcifications and impact on local control. Cancer, 2005 Jun 1;103(11):2236-40.
    • Yu Z, Weinberger PM, Provost E, Haffty BG , Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. {beta}-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 11(7):2471-2477, 2005.
    • Smith BD, Smith GL, Haffty BG . Post-mastectomy radiation and mortality in women with T1-2,N+ breast cancer. J Clin Oncol 23(7):1409-1419, 2005.
    • Haffty BG , Wilson LD, Son YH, Cho EI, Papac R, Fischer DB, Rockwell S, Sartorelli AC, Ross DA, Sasaki CT, Fischer JJ. Concurrent chemo-radiotherapy with mitomycin C compared with porfiromycin in squamous cell cancer of the head and neck: Final results of a randomized clinical trial. Int J Radiat Oncol Biol Phys 61(1):119-128, 2005.
    • Solin LJ, Fourquet A, Vicini FA, Taylor M, Olivotto JA, Haffty B , Strom EA, Pierce LJ, Marks LB, Bartelink H, McNeese MD, Jhingran A, Wai E, Bijker N, Campana F, Hwang WT. Long-term outcome after breast-conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 103(6): 1137-1146, 2005.
    • Yu Z, Weinberger PM, Haffty BG , Sasaki C, Zerillo C, Joe J, Kowalski D, Dziura J, Camp RL, Rimm DL, Psyrri A. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 11(2):1160-1166, 2005.
    • Alpert TE Haffty BG . Safety of breast conservation therapy in BRCA1 and BRCA2 cancers. Breast Cancer Online 7:1-10, 2004.
    • Wilson LD, Haffty BG . Radiation Oncology, The New Deal, Yale J Biol Med 76:125-127, 2004.
    • Moran M, Lund MW, Ahmad M, Trumpore HS, Haffty B , Nath R. Improved treatment of pelvis and inguinal nodes using modified segmental boost technique: Dosimetric evaluation. Int J Radiat Oncol Biol Phys 59(5):1523-1540, 2004.
    • Kuerer HM, Arthur DW, Haffty BG . Repeat breast-conserving surgery for in-breast local breast carcinoma recurrence. Cancer 100(11):2269-2280, 2004.
    • A.Psyrri, M. Kwong, L. Lekakis, M. Kassar, C. Sasaki, L. Wilson, B. Haffty , Y.H. Son, D.A. Ross, P. Weinberger, G. Chung, D. Zelterman, B.A. Burtness and D.L. Cooper. Cisplatin, 5-Fluorouracil and Leucovorin (PFL) induction chemotherapy followed by concurrent Cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22(15):30061-3069, 2004.
    • P.M. Weinberger, Z. Yu, B.G. Haffty , M. Harigopal, D. Kowalski, C. Sasaki, D.L. Rimm and A. Psyrri. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clinical Cancer Research 10(17):5684-5691, 2004.
    • Ahn PH, Thanh Vu H, Lannin D, Obedian E, DiGiovanna MP, Burtness B, Haffty BG . Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23(1):17-23, 2005.
    • Cho EI, Kowalsi DP, Sasaki CT, Haffty BG . Tissue microarray analysis reveals prognostic significance of COX-2 expression of local relapse in T1-2N0 larynx cancer treated with primary radiation therapy. Laryngoscope 114(11):2001-2008, 2004.
    • Cho EI, Sasaki CT , Haffty BG . Prognostic significance of pretreatment hemoglobin for local control and overall survival in T1-T2N0 larynx cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 58(4):1135-40, 2004.
    • Chang BW, Kim DH, Kowalski DP, Burleson JA, Son YH, Wilson LD, Haffty BG . Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 10(5):1678-84. 2004.
    • Lannin DR , Haffty BG . End results of salvage therapy after failure of breast-conservation surgery. Oncology ( Huntington ). 2004 Mar;18(3):272-9; discussion 280-2, 285-6, 292.
    • Choi DH, Lee MH, Bale AE, Carer D, Haffty BG . Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients. J Clin Oncol 1;22(9):1638-45, 2004.
    • Alpert TE, Haffty BG . Conservative management of breast cancer in BRCA1/2 mutation carriers. Clin Breast Cancer. 5(1):37-42, 2004.
    • Colasanto JM, Haffty BG , Wilson LD. Evaluation of local recurrence and second malignancy in patients with T1 and T2 squamous cell carcinoma of the larynx. Cancer J 10(1):61-66, 2004.
    • Haffty BG , Hauser A, Choi DH, Parisot N, Rimm D, King B, and Carter D. Molecular markers for prognosis following isolated postmastectomy chest wall recurrence. Cancer 100(2):25-263, 2004.
    • Cho EI, Sasaki CT , and Haffty BG. Prognostic significance of pretreatment hemoglobin for local control and overall survival in T1-2N0 larynx cancer treated with external beam radiotherapy. Int J Rad Onc Biol Phys 58(4):1135-1140, 2004.
    • Bou-Khalil J, Rose M, Psyrri A, D'Andrea E, Medoff E, Staugaard-Hahn C, Holtkamp C, Gran S, Pezzimente J, Snyder E, Cooper D, Haffty B , Reiss M, Burtness B. Sequential high-dose alkylating therapy and stem cell support for high-risk stage III breast cancer. Breast J 9(6):472-477, 2003.
    • Xie W, Bharathy S, Kim D, Haffty BG , Rimm DL, Reiss M. Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res 14(2):61-73, 2003.
    • Choi DH , Shin DB, Lee MH, Lee DW , Dhandapani D, Carter D, King B L, and Haffty BG . A comparison of five immunohistochemical biomarkers and HER-2/ neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma. Cancer 98(8):1587-1595, 2003.
    • Wilson LD, Haffty BG. Evaluation of the National Resident Matching Program (NRMP) radiation oncology data (1993-2003). Int J Radiat Oncol Biol Phys 57(4):1033-1037, 2003.
    • Haffty BG , Glazer PM. Molecular markers in clinical radiation oncology. Oncogene. 22(37):5915-25, 2003.
    • Tuamokumo NL, Haffty BG . Clinical outcome and cosmesis in African-American patients treated with conservative surgery and radiation therapy. Can J Sci Am. 9(4):313-20,2003.
    • Marshall JK, Griffith KA, Haffty BG , Solin LJ, Vicini FA, McCormick B, Wazer DE, Recth A, Pierce LJ. The conservative management of Paget's Disease of the breast with radiotherapy:10 and 15 year results. Cancer 97(9):2142-2149, 2003.
    • Kim S, Rimm D, Carter D, Khan A, Parisot N, Alvarez-Franco M, Bale A, Haffty BG . BRCA status molecular markers and clinical variables in early conservatively managed breast cancer. Breast J. May-Jun;9(3):167-174, 2003.
    • Rodrigues NA, Dillon D, Carter D, Parisot N, Haffty BG . Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Cancer 97(6):1393-1403, 2003.